Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Lowsky

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Research Square|November 24, 2025
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasMark P Hamilton, Nick Phillips, Troy Noordenbos, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Research Square|November 24, 2025
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasMark P Hamilton, Nick Phillips, Troy Noordenbos, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 7